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OBJECTIVES Patients with high triglyceride (of which very low density lipoproteins [VLDL] are the main
carriers), but with normal low density lipoprotein (LDL) cholesterol levels, were examined for
in vivo endothelium function status.
BACKGROUND Very low density lipoproteins inhibit endothelium-dependent, but not -independent, vasore-
laxation in vitro.
METHODS Three groups were studied: 1) healthy volunteers (n 5 10; triglyceride 1.24 6 0.14
mmol/liter, LDL cholesterol 2.99 6 0.24 mmol/liter); 2) hypertriglyceridemic (n 5 11;
triglyceride 6.97 6 1.19 mmol/liter,* LDL cholesterol 2.17 6 0.2 mmol/liter, *p , 0.05); and
3) hypercholesterolemic (n 5 10; triglyceride 2.25 6 0.29 mmol/liter,* LDL cholesterol
5.61 6 0.54 mmol/liter*; *p , 0.05) patients. Vasoactive responses to acetylcholine, sodium
nitroprusside, noradrenaline, NG-monomethyl-L-arginine and postischemic hyperemia were
determined using forearm venous occlusion plethysmography.
RESULTS Responses to acetylcholine (37 mg/min) were significantly dampened both in hypercholes-
terolemic (% increase in forearm blood flow: 268.2 6 62) and hypertriglyceridemic patients
(232.6 6 45.2) when compared with controls (547.8 6 108.9; ANOVA p , 0.05). Responses
to sodium nitroprusside (at 1.6 mg/min: controls vs. hypercholesterolemics vs. hypertriglyc-
eridemic: 168.7 6 25.1 vs. 140.6 6 38.9 vs. 178.5 6 54.5% increase), noradrenaline,
NG-monomethyl-L-arginine and postischemic hyperemic responses were not different among
the groups examined.
CONCLUSIONS Acetylcholine responses are impaired in patients with pathophysiologic levels of plasma
triglycerides but normal plasma levels of LDL cholesterol. The impairment observed was
comparable to that obtained in hypercholesterolemic patients. We conclude that impaired
responses to acetylcholine normally associated with hypercholesterolemia also occur in
hypertriglyceridemia. These findings identify a potential mechanism by which high plasma
triglyceride levels may be atherogenic independent of LDL cholesterol levels. (J Am Coll
Cardiol 1999;33:805–12) © 1999 by the American College of Cardiology
Hypercholesterolemia is associated with impaired
endothelium-dependent dilatation even in the absence of
atherosclerotic plaques (1). This has been evidenced in
humans by a reduction in responses to the muscarinic
agonist acetylcholine in resistance arteries of the upper limbs
(vessels not prone to the development of atherosclerotic
lesions) with preserved responses to the non-endothelium-
dependent nitrovasodilator sodium nitroprusside (2,3). This
finding has also been described in angiographically normal
coronary arteries of patients with hypercholesterolemia (4).
The way in which the impairment occurs is unclear, and it
is likely that there is contribution from more than one
mechanism. Low density lipoproteins (LDL) isolated from
human plasma alter vasomotion through inhibition of
endothelium-dependent relaxation (5,6). In most ex vivo
studies, oxidized LDL appears to play a major role (7) and
has been postulated to impair signal transduction between
endothelial cell surface receptors and nitric oxide production
(8). This has also been shown to be true of nonmodified
LDL (9). Other possibilities include the inhibition of nitric
oxide synthase expression (10) and the inactivation of nitric
oxide released from the endothelium (11).
That elevated levels of LDL cholesterol impair
endothelium-dependent relaxation is evident from a num-
ber of studies. Thus, a normalized response to acetylcholine
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occurs following reduction of plasma LDL levels using
lipid-lowering therapy (3,12,13). Even a single session of
LDL apheresis (resulting in the reduction of total LDL and
oxidized LDL) improves endothelium function, assessed as
an increased vasorelaxation response to acetylcholine as well
as an enhanced production of metabolites of nitric oxide
during acetylcholine infusion (14). In addition, the degree
of impairment of acetylcholine-induced vasomotor response
appears to be related to the LDL cholesterol level after
therapy (12).
We reported recently that very low density lipoproteins
(VLDL) isolated from human plasma inhibit vasorelaxation
mediated by endothelium-dependent but not independent
dilators in isolated rat aortic rings (6). As an extension to
these in vitro studies, patients with high triglyceride levels
(of which VLDLs are the main carriers), but with normal
LDL cholesterol levels, were examined for in vivo endothe-
lium function status. Although an association between
plasma triglyceride levels and coronary heart disease has
been postulated (15,16), the role of triglyceride-rich li-
poproteins per se in the etiology of coronary artheroma
remains uncertain. Because an impaired response to nitric
oxide-generated vasorelaxation may predispose to coronary
vasospasm (17) and also contribute to the atherogenic
process by promoting abnormal interactions between the
vascular wall and platelets, neutrophils and macrophages
(18,19), the current study lends insight into potential
mechanisms for such a role.
METHODS
Three study groups were recruited: normal volunteers (n 5
10; all men) by advertisement, and hypercholesterolemic
(n 5 10; 1 woman) and hypertriglyceridemic (n 5 11; 1
woman) subjects from the Lipid Clinic at the Heart Centre,
Alfred Hospital, Melbourne, Australia. All volunteers had
normal findings on physical examination and no abnormal-
ities on routine hematology and biochemical blood analyses,
with the exception of defined plasma lipid changes. Subjects
were classified as control subjects: triglyceride levels ,2.00
mmol/liter and LDL cholesterol ,3.50 mmol/liter; hyper-
cholesterolemic subjects: triglyceride levels ,2.50 mmol/
liter and LDL cholesterol .5.00 mmol/liter; hypercholes-
terolemic subjects: triglyceride levels .6.5 mmol/liter and
LDL cholesterol ,3.5 mmol/liter. Exclusion criteria in-
cluded: hypertension, cigarette smoking within 6 months,
medication or vitamin supplements or a history of heart
disease, diabetes or any other major illness. Hypercholester-
olemic subjects taking lipid-lowering therapy (n 5 2) were
asked to cease therapy for a minimum of two weeks prior to
the day of study. None of the hypertriglyceridemic subjects
were taking lipid-lowering therapy. All hypertriglyceridemic
patients had a fasting glucose of less than 6 mmol/liter
(5.15 6 0.23 mmol/liter) at the time of study. The exper-
imental protocol was approved by the Alfred Group of
Hospitals Ethics Committee, and written informed consent
was obtained from all subjects, who were also aware of their
right to withdraw from the study at any time of their choice.
Experimental protocol. Subjects were studied after an
overnight fast. Under strict aseptic conditions and local
anesthesia (lignocaine 1%) the nondominant brachial artery
was cannulated (3F, 5-cm catheter; Cook, Australia) for
intra-arterial pressure recordings and drug infusions. A
20-ml blood sample was withdrawn for subsequent lipopro-
tein analysis. Arterial blood pressure was recorded with an
AE 840 physiologic pressure transducer throughout the
course of each experiment. Forearm blood flow was mea-
sured with venous occlusion plethysmography with a double
sealed, alloy-filled (gallium and indium), double-strand
strain gauge (Medasonic, Mountain View, California), with
venous occlusion at 40 to 50 mm Hg for 10 out of every
20 s. Hand blood flow was occluded by a wrist cuff inflated
to 200 mm Hg at the time of blood flow measurement.
To examine vascular reactivity after ischemia, forearm
blood flow was occluded proximally on the upper arm at
200 mm Hg for 5 min. Forearm blood flow postischemia
was measured every 20 s for 2 min or until a plateau in blood
flow was attained. In addition, blood flow responses were
examined after discrete sequential infusions of acetylcholine
(ACh: 9.25, 18.5 and 37 mg/min), sodium nitroprusside
(SNP: 0.4, 0.8 and 1.6 mg/min), norepinephrine (NE: 25,
50 and 100 ng/min) and NG-monomethyl-L-arginine (L-
NMMA; 4 mmol/min). Each drug was infused at 2 ml/min
over a maximum of 7 min or until the response over three
flow measurements reached a plateau (with the exception of
L-NMMA, usually by 3 min). Rest periods of 5 min
between concentrations and 10 min between drugs were
observed. Physiologic saline (0.9%) was infused during rest
periods. Basal blood flow (the mean of three flow measure-
ments) was obtained just before each intervention.
Resting blood pressure was recorded 30 min after the
cannulation procedure, before the start of flow measure-
ments. To account for between-subject basal variation of
forearm blood flow (20), results were expressed as a per-
centage change compared with the basal forearm blood flow
present immediately prior to each infusion or to ischemia.
Lipoprotein analysis. Plasma lipoproteins were isolated by
a combination of ultracentrifugation and selective precipi-
tation. Both VLDL and chylomicrons were isolated as a
floating fraction at a density of 1.006 after being spun for a
minimum of 16 h at 40,000 rpm at 20°C in quickseal
polyallomer ultracentrifuge tubes (Beckman 34619). Tubes
were sliced 15 mm from the top; the bottom fraction was
treated with heparin/Mn11 to precipitate LDL, leaving
high density lipoprotein (HDL) in solution. Lipid measure-
ments were made of whole plasma, top fraction (VLDL)
and bottom fraction (LDL and HDL) and of the heparin-
ized supernatant (HDL). The LDL parameters were calcu-
lated by subtracting the supernatant from the bottom
fraction value. Analytical kits from Boehringer Mannheim
were used for measurement of total cholesterol (237574),
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free cholesterol (310329), triglyceride without free glycerol
(450032), phospholipid (691844), apolipoprotein A1
(1378686) and apolipoprotein B (1378694). Calibrators
(759350; Precipath 781827) and normal (Precinorm
1285874) control sera were also from Boehringer Mann-
heim. Kits for lipoprotein(a) were from Incstar (Atlantic
Antibodies ATA 86084).
LDL particle sizes. Individual plasma samples were frozen
at 280°C. The LDL was isolated by a two-step gradient
ultracentrifugation method (21); LDL particle diameters
were determined on 3% to 13% nondenaturing gradient gels
(Gradipore GS313). An LDL sample was loaded onto a
gradient gel, adjacent to which was loaded a lane with
Polystyrene Latex Microspheres 28-nm diameter (Duke
5003A) and a lane of High Molecular Weight standards
(Pharmacia 17-0445-01). Electrophoresis was carried out in
nondenaturing running buffer for 16 h at 190 V with
circulation at 10°C; gels were fixed with 10% sulphosalicylic
acid for 1 h, stained with 0.04% PAGE Blue G90 (Electran
44248) for 3 h and destained with 5% acetic acid overnight
or until the background was clear. The LDL peak sizes were
estimated against a standard curve created from the markers
of known diameter: latex 28 nm, thyroglobulin 17 nm,
ferritin 12.2 nm, and catalase 10.4 nm. We have previously
demonstrated that there is no significant difference between
fresh and frozen LDL prepared from aliquots stored at
280°C for up to 3 months (22).
The LDL particle sizes were quantified for each peak in
every individual subject. As noted previously (22) some
subjects had more than one LDL peak. In these cases the
diameter of each peak was determined as well as the
percentage contribution of each LDL peak to the total area
under all peaks. The weighted average LDL diameter was
then determined for each subject. There was, however, no
significant difference between the peak of the major LDL
sphere and the weighted LDL diameter, and virtually
identical results were obtained in all statistical analyses
whether the diameter of the major peak or the weighted
average was used. Thus, the data shown pertain to the LDL
diameter of the major peak.
Data analysis. Data are presented as mean 6 standard
error mean (SEM). Comparison of anthropometric, hemo-
dynamic and lipid data between groups was performed by
analysis of variance (ANOVA) followed by the Student
unpaired t test, using SigmaStat (Version 2.03) Statistical
Software (Jandel Scientific, San Rafael, California), which
analyzes data for normality prior to performing parametric
analysis. Nonparametric data were examined by a Mann-
Whitney Rank Sum test. Responses to various agonists were
performed using two-way repeated measures ANOVA (Jan-
del Scientific, San Rafael, California) followed where sig-
nificant by a Student-Newman-Keuls test. The level of
statistical significance employed was p , 0.05.
RESULTS
Anthropometric data. Control subjects did not differ from
either the hypercholesterolemic or hypertriglyceridemic
groups in age or in either systolic or diastolic blood pressure.
Body mass index (BMI) was significantly higher in the
hypertriglyceridemic subjects when compared with control
subjects. There was no difference in BMI between control
and hypercholesterolemic subjects (see Table 1).
Plasma lipid and lipoprotein fractions. Plasma lipids and
lipoprotein composition are shown in Tables 2 and 3.
Hypercholesterolemic subjects were characterized by ele-
vated LDL cholesterol, and hypertriglyceridemic subjects by
elevated VLDL triglyceride concentrations. Plasma phos-
pholipids were elevated in both hyperlipidemic groups
compared with controls. Moreover, VLDL phospholipids
were elevated in both hyperlipidemic groups, but LDL
phospholipids were elevated only in the hypercholester-
olemic group compared with control subjects. The LDL
particles were significantly smaller in both hyperlipidemic
groups when compared with the control group.
Forearm blood flow. Basal forearm blood flow at rest was
not different among the three groups (ml/100 ml/min:
control vs. hypercholesterolemic vs. hypertriglyceridemic:
2.91 6 0.55 vs. 2.80 6 0.40 vs. 1.71 6 0.15; one-way
ANOVA; p 5 NS). Vasodilatory responses to acetylcholine
were dose-dependent in the three groups. These responses
were significantly dampened both in patients with high
triglycerides and in patients with high cholesterol levels
Table 1. Age, Body Mass Index and Systolic and Diastolic Blood Pressure in Control (n 5 10)
Compared With Hypertriglyceridemic (HTg; n 5 11) and Hypercholesterolemic (HCh; n 5
10) Subjects
Control
Subjects HTg Subjects
HCh
Subjects
Age (yrs) 45.4 6 3.8 51.7 6 3.0 44.7 6 4.73
Body mass index (kg/m2) 25.02 6 0.30 30.10 6 1.03* 27.96 6 2.03
Systolic blood pressure (mm Hg) 130.4 6 3.83 135.0 6 3.48 133.3 6 5.73
Diastolic blood pressure (mm Hg) 69.3 6 3.03 71.0 6 2.26 72.8 6 2.24
Analysis by ANOVA followed where significant by pairwise multiple comparison procedure (Dunn’s method).
*p , 0.05 in comparison with controls.
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when compared to controls regardless of whether the data
were expressed as absolute forearm blood flow or as a %
increase in forearm blood flow (Fig. 1). The endothelium-
independent agonist sodium nitroprusside also induced
dose-dependent vasodilator responses. Although these re-
sponses were significantly dampened in patients with high
triglyceride levels when expressed as absolute forearm blood
flow, they did not differ when corrected for differences in
basal flow (Fig. 2).
Similarly, postischemic hyperemic responses were signif-
icantly dampened in patients with hypertriglyceridemia
when expressed as absolute forearm blood flow but did not
differ when corrected for differences in preischemic (basal)
forearm blood flows (Fig. 3). Neither responses to the
vasoconstrictor noradrenaline nor responses to the NO
synthase inhibitor L-NMMA differed among the three
groups studied, regardless of whether the data were ex-
pressed as absolute flow or when corrected for basal flow
(Fig. 4).
DISCUSSION
We have demonstrated, for the first time, impaired
endothelium-dependent relaxation to acetylcholine in sub-
jects with elevated plasma triglyceride but normal LDL
cholesterol levels. This impairment was comparable to that
observed in patients with high cholesterol levels, and we
conclude that the dampened response to this agonist nor-
mally associated with high plasma levels of cholesterol is not
specific to this lipid but is also true of another form of
hyperlipidemia. We conclude that a dampened response to
Table 2. Total Plasma Lipoprotein Compositions in Control (n 5 10) Compared With
Hypertriglyceridemic (HTg; n 5 11) and Hypercholesterolemic (HCh; n 5 10) Subjects
Plasma
Control
Subjects HTg Subjects HCh Subjects
Total cholesterol (mmol/liter) 4.55 6 0.29 5.23 6 0.36 7.16 6 0.41**
Free cholesterol (mmol/liter) 0.99 6 0.09 1.51 6 0.13* 1.54 6 0.10*
Esterified cholesterol (mmol/liter) 3.48 6 0.27 4.00 6 0.35 5.86 6 0.45*
Triglycerides (mmol/liter) 1.24 6 0.14 6.97 6 1.19* 2.24 6 0.33*
Phospholipids (mmol/liter) 2.40 6 0.13 3.30 6 0.38* 3.32 6 0.18*
Apolipoprotein A1 (mg/dl) 127.15 6 6.67 105.8 6 5.77 110.5 6 7.05
Apolipoprotein B (mg/dl) 92.88 6 7.48 83.5 6 10.77 157.6 6 20.68*
Lipoprotein (a) (mg/dl) 15 (9.04, 37.1)† 11.2 (5.0, 18.0)† 25.5 (15.32, 27.4)†
*p , 0.05 values in comparison with controls. † Median (range) shown as data are normally distributed.
Table 3. Lipoprotein Compositions in Control (n 5 10) Compared With Hypertriglyceridemic
(HTg; n 5 11) and Hypercholesterolemic (HCh; n 5 10) Subjects
Lipoprotein Fractions
(mmol/liter)
Control
Subjects HTg Subjects HCh Subjects
Very low density lipoprotein
Total cholesterol 0.32 6 0.05 2.13 6 0.26* 0.84 6 0.16*
Free cholesterol 0.10 6 0.01 0.89 6 0.09* 0.27 6 0.05*
Esterified cholesterol 0.22 6 0.05 1.59 6 0.19* 0.50 6 0.10*
Triglycerides 0.87 6 0.33 5.19 6 0.98* 1.42 6 0.26*
Phospholipids 0.19 6 0.03 1.17 6 0.18* 0.49 6 0.08*
Low density lipoprotein
Total cholesterol 2.94 6 0.31 2.17 6 0.2 5.17 6 0.34*
Free cholesterol 0.62 6 0.07 0.39 6 0.04* 1.05 6 0.09*
Esterified cholesterol 2.34 6 0.25 1.94 6 0.20 4.32 6 0.34*
Triglycerides 0.24 6 0.02 0.82 6 0.36* 0.23 6 0.02*
Phospholipids 1.04 6 0.08 1.01 6 0.12 1.81 6 0.14*
Particle size (mm) 24.80 6 0.11 23.90 6 0.20* 24.30 6 0.15*
High density lipoprotein
Total cholesterol 1.07 6 0.12 1.15 6 0.43 0.97 6 0.07
Free cholesterol 0.13 6 0.03 0.07 6 0.11 0.09 6 0.01
Esterified cholesterol 0.94 6 0.10 0.72 6 0.06 0.83 6 0.07
Triglycerides 0.14 6 0.01 0.55 6 0.27* 0.17 6 0.02
Phospholipids 1.06 6 0.08 0.83 6 0.06* 0.96 6 0.09
*p , 0.05 values in comparison with controls.
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acetylcholine occurs with high plasma triglyceride levels
independently of LDL cholesterol levels.
Inclusion of the small number of women. The inclusion
of the two women into our study was reexamined following
reports of sex differences on endothelium function (23).
Both the women studied were postmenopausal and not on
hormone replacement therapy. Nevertheless, the entire data
set was analyzed excluding the contributions of both
women. As the findings were similar with or without their
inclusion, we opted to include the total data set to allow for
the larger study groups.
Basal forearm blood flow: Effect of vasodilatory re-
sponses. Further to the finding of a dampened response to
acetylcholine, we observed a tendency for patients with
hypertriglyceridemia to have a depressed basal forearm
blood flow, suggesting a basal vasoconstrictive state (1.71 6
0.15 ml/100 ml/min in hypertriglyceridemics vs. 2.91 6
0.55 in controls; p 5 NS on ANOVA), which was not
observed in patients with hypercholesterolemia (2.80 6 0.40
ml/100 ml/min). Starting from this lower basal flow level,
responses to both the direct-acting smooth muscle vasodi-
lator, sodium nitroprusside, and to postischemic vasodilata-
tion were significantly dampened in hypertriglyceridemics,
implicating a more general vasoconstrictive profile in these
patients. In contrast to responses to acetylcholine, however,
the dampened effects to both these stimulants were no
longer evident when responses were corrected for basal
forearm blood flow. The null effect of hyperlipidemia on
responses to sodium nitroprusside would suggest that the
impairment is at the level of the endothelium rather than
smooth muscle cell. Further, as postischemic vasodilatation
has been shown in part to be due to endothelial release of
Figure 1. Dose-dependent vasodilatory responses to acetylcholine
in controls and in patients with hypercholesterolemia and hyper-
triglyceridemia. Top panel shows responses expressed as absolute
forearm blood flow; bottom panel as % increase in basal forearm
blood flow. Analysis was by two-way repeated measures (RM)
ANOVA followed by Student-Newman-Keuls test (*p , 0.05
when compared to control point). Results are expressed as mean 6
standard error of the mean.
Figure 2. Dose-dependent vasodilatory responses to sodium ni-
troprusside in controls and in patients with hypercholesterolemia
and hypertriglyceridemia. Top panel shows responses expressed as
absolute forearm blood flow; bottom panel as % increase in basal
forearm blood flow. Analysis was by two-way repeated measures
(RM) ANOVA followed by Student-Newman-Keuls test (*p ,
0.05 when compared to control point). Results are expressed as
mean 6 standard error of the mean.
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nitric oxide (24) and because these responses were not
altered in either group, we suggest that this is further
evidence supporting the hypothesis (25) that endothelium-
dependent impairment associated with hyperlipidemia may,
in the early stages, be restricted to pertussis-toxin-sensitive
stimulants such as acetylcholine, leaving pertussis-toxin-
insensitive stimulation, such as shear stress (26), unaffected.
Basal forearm blood flow: Effect of vasoconstrictory
responses. Regulation of basal vascular tone is partially
regulated by nitric oxide. Inhibition of nitric oxide produc-
tion by infusion of L-NMMA, an inhibitor of nitric oxide
synthase, provides an index of basal nitric oxide production.
We report an equal depression of forearm blood flow
following L-NMMA infusion in the three subject groups
examined, confirming previous reports of unaltered basal
nitric oxide production in hypercholesterolemic subjects
(13). In addition, the current results demonstrate no effect
of elevated triglycerides on basal nitric oxide production.
Further evidence supporting unchanged basal nitric oxide
production in the presence of hyperlipidemia was the similar
contractile responses to noradrenaline in all three groups.
Other studies examining other contractile agonists, such as
phenylephrine, have also reported no difference between
control and hypercholesterolemic subjects (27).
Possible mechanisms of action. Previous human (12)
studies have reported on an inverse relationship between the
level of total and LDL cholesterol and impaired
endothelium-dependent relaxation. We have now shown
that subjects with elevated triglyceride but normal LDL
cholesterol levels also have impaired endothelium-
dependent relaxation. We can discount undiagnosed diabe-
Figure 3. Responses are shown before (220 s) and that obtained
immediately (0 s; peak flow) and 20, 40, 60, 80, 100, 120, 140 and
160 s following 5 min of upper arm ischemia. Top panel shows
responses expressed as absolute forearm blood flow; bottom panel
as % increase in basal forearm blood flow. Analysis was by two-way
repeated measures (RM) ANOVA followed by Student-Newman-
Keuls test (*p , 0.05 when compared to control point). Results are
expressed as mean 6 standard error of the mean.
Figure 4. Top panel: Dose-dependent decreases in forearm blood
flow are shown in response to noradrenaline in controls and in
patients with hypercholesterolemia and hypertriglyceridemia.
Analysis was by two-way repeated measures (RM) ANOVA.
Bottom panel: The % decrease is shown in basal forearm blood
flow following infusion with NG-monomethyl-L-arginine (L-
NMMA) 4 mmol/min in controls, hypercholesterolemics and
hypertriglyceridemics. Analysis was by one-way ANOVA. Results
are expressed as mean 6 standard error of the mean.
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tes as a possible cause for the impairment in the hypertri-
glyceridemic subjects as all the patients studied had a fasting
glucose level of less than 6.0 mmol/liter at the time of study.
The finding that both an elevated LDL cholesterol and
an elevation of triglyceride-enriched lipoproteins can impair
endothelium-dependent vasodilation may imply that there
is more than one mechanism leading to impairment or there
may be other features common to these patient groups that
are responsible. Some studies have suggested that LDL
oxidation amplifies the inhibitory effect of LDL on
endothelium-dependent relaxation (7). In addition, small
dense particles, which may themselves be prone to oxida-
tion, are particularly responsible (28). Because small dense
LDL particles are a feature of both hypercholesterolemia
and hypertriglyceridemia, we speculate that this may be a
potential common pathway causing impaired endothelium-
dependent vasodilation.
The current results are consistent with those of Vogel and
colleagues (29), who demonstrated that mean changes in
postprandial flow-mediated vasoactivity at 2, 3 and 4 h
correlate significantly with changes in serum triglyceride
levels. Conversely, our findings of impaired endothelium
function in hypertriglyceridemics are in direct contrast to
those reported by Chowienczyk et al. (30) where patients
with severe hypertriglyceridemia, but normal LDL choles-
terol levels, exhibited normal responses to ACh. A potential
difference between the two studies is the significantly higher
BMI in the subjects of the current study compared with the
controls. Although univariate analysis revealed no correla-
tion between BMI and maximum response obtained to
ACh (data not shown), the significantly higher BMI may be
indicative that the current patient group had insulin-
resistance syndrome, a possibility that was not examined.
Conclusions. In conclusion, we have found that
endothelium-dependent relaxation mediated by acetylcho-
line is impaired both in subjects with hypertriglyceridemia
and in subjects with hypercholesterolemia. The design of
this study precludes us from determining the mechanism by
which elevated lipids impair endothelium-dependent relax-
ation, but it suggests that the endothelial impairment
normally associated with high plasma levels of LDL cho-
lesterol is not specific to these lipids but is also true of high
triglyceride levels. These findings identify a potential mech-
anism by which high plasma triglyceride levels may be
atherogenic-independent of LDL cholesterol levels.
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